Chunk #15 — Current Status of Drug Labeling and Pharmacogenomic Testing Guidelines — Guidelines and Labeling for Carbamazepine

Source

Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Embedded

yes

Text

highest frequencies in Asian populations (10–15% in patients from China, Thailand, Malaysia, Indonesia, the Philippines, and Taiwan; 2–4% in patients from south Asia and India), with extremely low or nonexistent(<0.01%) in patients of European, Hispanic, Native American, and African descent.28 The HLA-B*1502 allele appears to cosegregate with two polymorphisms (rs2844682 and rs3909184) that are thought to result in altered immune system recognition to carbamazepine that bypasses antigen processing involved in direct presentation to cytotoxic T cells and subsequent cytotoxicity.29